Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M™ vaccination.

Autor: Alter G; Ragon Institute of MGH, MIT and Harvard., Gorman M; Ragon Institute of MGH, MIT, and Harvard., Patel N; Novavax Inc., Guebre-Xabier M; Novavax Inc., Zhu A; Ragon Institute of MGH, MIT, and Harvard., Atyeo C; Ragon Institute of MGH, MIT and Harvard., Pullen K; Massachusetts Institute of Technology., Loos C; Ragon Institute of MGH, MIT, and Harvard., Goez-Gazi Y; Texas Biomedical Research Institute., Carrion R Jr; Texas Biomedical Research Institute., Tian JH; Novavax Inc., Yuan D; Ragon Institute of MGH, MIT, and Harvard., Bowman K; Ragon Institute of MGH, MIT, and Harvard., Zhou B; Novavax Inc., Maciejewski S; Novavax Inc., McGrath M; University of Maryland., Logue J; University of Maryland School of Medicine., Frieman M; University of Maryland School of Medicine., Montefiori D; Duke University., Schendel S; La Jolla Institute for Immunology., Saphire EO; La Jolla Institute for Immunology., Lauffenburger D; Massachusetts Institute of Technology., Greene A; Novavax Inc., Portnoff A; Novavax Inc., Massare M; Novavax Inc., Ellingsworth L; Novavax Inc., Glenn G; Novavax, Inc., Smith G; Novavax, Inc., Mann C; La Jolla Institute for Immunology., Amanat F; Icahn School of Medicine at Mount Sina., Krammer F; Icahn School of Medicine at Mount Sinai.

Publikováno v: Research square [Res Sq] 2021 Feb 15. Date of Electronic Publication: 2021 Feb 15.